- Home
- IBRX vs CSQ Comparison
IBRX vs CSQ Comparison
Compare IBRX & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CSQ
- Stock Information
- Founded
- IBRX 2014
- CSQ 2003
- Country
- IBRX United States
- CSQ United States
- Employees
- IBRX N/A
- CSQ N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CSQ Finance Companies
- Sector
- IBRX Health Care
- CSQ Finance
- Exchange
- IBRX Nasdaq
- CSQ Nasdaq
- Market Cap
- IBRX 2.4B
- CSQ 2.8B
- IPO Year
- IBRX N/A
- CSQ N/A
- Fundamental
- Price
- IBRX $4.49
- CSQ $17.64
- Analyst Decision
- IBRX Buy
- CSQ
- Analyst Count
- IBRX 2
- CSQ 0
- Target Price
- IBRX $17.38
- CSQ N/A
- AVG Volume (30 Days)
- IBRX 10.4M
- CSQ 220.3K
- Earning Date
- IBRX 11-12-2024
- CSQ 01-01-0001
- Dividend Yield
- IBRX N/A
- CSQ 7.53%
- EPS Growth
- IBRX N/A
- CSQ N/A
- EPS
- IBRX N/A
- CSQ N/A
- Revenue
- IBRX $7,332,000.00
- CSQ N/A
- Revenue This Year
- IBRX $1,563.18
- CSQ N/A
- Revenue Next Year
- IBRX $1,262.20
- CSQ N/A
- P/E Ratio
- IBRX N/A
- CSQ N/A
- Revenue Growth
- IBRX 1218.71
- CSQ N/A
- 52 Week Low
- IBRX $3.10
- CSQ $12.50
- 52 Week High
- IBRX $10.53
- CSQ $16.45
- Technical
- Relative Strength Index (RSI)
- IBRX 46.07
- CSQ 48.84
- Support Level
- IBRX $4.57
- CSQ $17.16
- Resistance Level
- IBRX $5.08
- CSQ $18.18
- Average True Range (ATR)
- IBRX 0.54
- CSQ 0.20
- MACD
- IBRX -0.12
- CSQ -0.00
- Stochastic Oscillator
- IBRX 3.16
- CSQ 43.64
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's investment strategy is to provide total return through a combination of capital appreciation and current income. Its investment portfolio consists of equities, convertible securities and high-yield corporate bonds.